These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 18787352)

  • 1. Weekly vinorelbine versus docetaxel for metastatic breast cancer after failing anthracycline treatment.
    Meier CR; Illiger HJ; Steder M; Janssen J; Deertz H; Braun M; Oeney HT; Deuss B; Küchler T; Rotermund S
    Onkologie; 2008 Sep; 31(8-9):447-53. PubMed ID: 18787352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Late phase II clinical study of vinorelbine monotherapy in advanced or recurrent breast cancer previously treated with anthracyclines and taxanes.
    Toi M; Saeki T; Aogi K; Sano M; Hatake K; Asaga T; Tokuda Y; Mitsuyama S; Kimura M; Kobayashi T; Tamura M; Tabei T; Shin E; Nishimura R; Ohno S; Takashima S
    Jpn J Clin Oncol; 2005 Jun; 35(6):310-5. PubMed ID: 15930037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II trial of docetaxel and vinorelbine in patients with advanced breast cancer previously treated with anthracyclines.
    Vici P; Di Lauro L; Sergi D; Foggi P; Viola G; Mottolese M; Giotta F; Fattoruso SI; Corsetti S; Giannarelli D; Botti C; Lopez M
    Oncology; 2008; 75(3-4):175-81. PubMed ID: 18841031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vinorelbine and docetaxel as first-line chemotherapy in metastatic breast cancer.
    Vassilomanolakis M; Koumakis G; Drufakou S; Aperis G; Demiri M; Barbounis V; Missitzis J; Efremidis AP
    Cancer Chemother Pharmacol; 2003 Feb; 51(2):179-83. PubMed ID: 12647021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective, open label, randomized phase II trial of weekly docetaxel versus weekly vinorelbine as first line chemotherapy in patients with androgen independent prostate cancer.
    Krainer M; Tomek S; Elandt K; Horak P; Albrecht W; Eisenmenger M; Höltl W; Schramek P; Stackl W; Zielinski C; Reibenwein J
    J Urol; 2007 Jun; 177(6):2141-5; discussion 2145. PubMed ID: 17509302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer.
    Gennari A; Guarneri V; Landucci E; Orlandini C; Rondini M; Salvadori B; Ricci S; Conte PF
    Clin Breast Cancer; 2002 Dec; 3(5):346-52. PubMed ID: 12533265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vinorelbine and capecitabine in anthracycline- and/or taxane-pretreated metastatic breast cancer: sequential or combinational?
    Zhang J; Gu SY; Gan Y; Wang ZH; Wang BY; Guo HY; Wang JL; Wang LP; Zhao XM; Hu XC
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):103-13. PubMed ID: 23053266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective multicenter randomized phase III study of weekly versus standard docetaxel plus doxorubicin (D4) for first-line treatment of metastatic breast cancer.
    Stemmler HJ; Harbeck N; Gröll de Rivera I; Vehling Kaiser U; Rauthe G; Abenhardt W; Artmann A; Sommer H; Meerpohl HG; Kiechle M; Heinemann V
    Oncology; 2010; 79(3-4):204-10. PubMed ID: 21358208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
    Jones A; O'Brien M; Sommer H; Nowara E; Welt A; Pienkowski T; Rolski J; Pham ML; Perraud K; Trillet-Lenoir V
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):755-63. PubMed ID: 19669644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Docetaxel plus cisplatin is effective for patients with metastatic breast cancer resistant to previous anthracycline treatment: a phase II clinical trial.
    Park SH; Cho EK; Bang SM; Shin DB; Lee JH; Lee YD
    BMC Cancer; 2005 Feb; 5():21. PubMed ID: 15723709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer.
    Bartsch R; Wenzel C; Altorjai G; Pluschnig U; Rudas M; Mader RM; Gnant M; Zielinski CC; Steger GG
    J Clin Oncol; 2007 Sep; 25(25):3853-8. PubMed ID: 17679724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective multicenter randomized phase III study of weekly versus standard docetaxel (D2) for first-line treatment of metastatic breast cancer.
    Stemmler HJ; Harbeck N; Gröll de Rivera I; Vehling Kaiser U; Rauthe G; Abenhardt W; Artmann A; Sommer H; Meerpohl HG; Kiechle M; Heinemann V
    Oncology; 2010; 79(3-4):197-203. PubMed ID: 21358207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node-positive breast cancer.
    Coombes RC; Bliss JM; Espie M; Erdkamp F; Wals J; Tres A; Marty M; Coleman RE; Tubiana-Mathieu N; den Boer MO; Wardley A; Kilburn LS; Cooper D; Thomas MW; Reise JA; Wilkinson K; Hupperets P
    J Clin Oncol; 2011 Aug; 29(24):3247-54. PubMed ID: 21768453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weekly combination of docetaxel and vinorelbine in metastatic breast cancer: a phase I/II study.
    Cals L; Nouyrigat P; Valenza B; Pedinelli FJ; Juin P
    Oncology; 2004; 67(3-4):257-61. PubMed ID: 15557787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients with HER2-positive metastatic breast cancer.
    Infante JR; Yardley DA; Burris HA; Greco FA; Farley CP; Webb C; Spigel DR; Hainsworth JD
    Clin Breast Cancer; 2009 Feb; 9(1):23-8. PubMed ID: 19299236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Weekly docetaxel in metastatic breast cancer patients: no superior benefits compared to three-weekly docetaxel.
    Schröder CP; de Munck L; Westermann AM; Smit WM; Creemers GJ; de Graaf H; Stouthard JM; van Deijk G; Erjavec Z; van Bochove A; Vader W; Willemse PH
    Eur J Cancer; 2011 Jun; 47(9):1355-62. PubMed ID: 21251813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II study of weekly docetaxel in patients with anthracycline pretreated metastatic breast cancer.
    Ford HE; Yap YS; Miles DW; Makris A; Hall M; Miller L; Harries M; Smith IE; Johnston SR
    Cancer Chemother Pharmacol; 2006 Dec; 58(6):809-15. PubMed ID: 16528527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase III study.
    Sparano JA; Makhson AN; Semiglazov VF; Tjulandin SA; Balashova OI; Bondarenko IN; Bogdanova NV; Manikhas GM; Oliynychenko GP; Chatikhine VA; Zhuang SH; Xiu L; Yuan Z; Rackoff WR
    J Clin Oncol; 2009 Sep; 27(27):4522-9. PubMed ID: 19687336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective study of vinorelbine and capecitabine combination therapy in Chinese patients with metastatic breast cancer pretreated with anthracyclines and taxanes.
    Fan Y; Xu B; Yuan P; Wang J; Ma F; Li Q; Zhang P; Li Q; Cai R
    Chemotherapy; 2010; 56(4):340-7. PubMed ID: 20720418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of metastatic breast cancer with vinorelbine and docetaxel.
    Savio G; Laudani A; Leonardi V; Pepe A; Scianna C; Gebbia V; Agostara B
    Am J Clin Oncol; 2006 Jun; 29(3):276-80. PubMed ID: 16755181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.